Drug Therapy for Parkinson's Disease

 

 Buy Article Permissions and Reprints

ABSTRACT

The fundamental concepts of the medical treatment of Parkinson's disease are simple, and remain based on the enhancement of dopaminergic transmission by means of levodopa and dopamine agonists. Recently published practice parameters from the American Academy of Neurology and an evidence-based review under the auspices of the Movement Disorder Society provide guidance on motor complications and also cognitive and psychiatric issues associated with Parkinson's disease. The choices of medications are increasing as are the routes of administration, with the arrival of injectable and transdermal dopamine agonists and a monoamine inhibitor absorbed via the buccal mucosa. Although simple conceptually, the actual care of patients with Parkinson's disease is often complex, requiring consideration of potential future complications and individualized medication regimens, and minimizing the adverse effects of medications that range from unpleasant to seriously disturbing.

REFERENCES

• 1 Pahwa R, Factor S A, Lyons K E et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 983-995
  CrossrefPubMedGoogle Scholar
• 2 Miyasaki J M, Shannon K, Voon V et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 996-1002
  CrossrefPubMedGoogle Scholar
• 3 Suchowersky O, Gronseth G, Perlmutter J et al.. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.  Neurology. 2006;  66 976-982
  CrossrefPubMedGoogle Scholar
• 4 Onuaguluchi G. Drug treatment of parkinsonism and its assessment. In: Vinken PJ, Bruyn GW Handbook of Clinical Neurology. New York; John Wiley & Sons Inc 1968: 218-226
  Google Scholar
• 5 Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease.  Cochrane Database Syst Rev. 2003;  (2) CD003735
  PubMedGoogle Scholar
• 6 Perry E K, Kilford L, Lees A J, Burn D J, Perry R H. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs.  Ann Neurol. 2003;  54 235-238
  CrossrefPubMedGoogle Scholar
• 7 Lloyd K G, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy.  J Pharmacol Exp Ther. 1975;  195 453-464
  PubMedGoogle Scholar
• 8 Cotzias G C, Papavasiliou P S, Gellene R. Experimental treatment of parkinsonism with L-Dopa.  Neurology. 1968;  18 276-277
  PubMedGoogle Scholar
• 9 Cotzias G C, Van Woert M H, Schiffer L M. Aromatic amino acids and modification of parkinsonism.  N Engl J Med. 1967;  276 374-379
  CrossrefPubMedGoogle Scholar
• 10 Fahn S, Oakes D, Shoulson I et al.. Levodopa and the progression of Parkinson's disease. Parkinson Study Group.  N Engl J Med. 2004;  351 2498-2508
  CrossrefPubMedGoogle Scholar
• 11 Parkinson Study Group . Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group.  Ann Neurol. 1996;  39 37-45
  CrossrefPubMedGoogle Scholar
• 12 Parkinson Study Group . Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.  JAMA. 2000;  284 1931-1938
  CrossrefPubMedGoogle Scholar
• 13 Rascol O, Brooks D J, Korczyn A D et al.. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group.  N Engl J Med. 2000;  342 1484-1491
  CrossrefPubMedGoogle Scholar
• 14 Blanchet P J, Calon F, Martel J C et al.. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.  J Pharmacol Exp Ther. 1995;  272 854-859
  PubMedGoogle Scholar
• 15 Bibbiani F, Costantini L C, Patel R, Chase T N. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.  Exp Neurol. 2005;  192 73-78
  CrossrefPubMedGoogle Scholar
• 16 Schrag A, Ben-Shlomo Y, Brown R et al.. Young-onset Parkinson's disease revisited: clinical features, natural history, and mortality.  Mov Disord. 1998;  13 885-894
  CrossrefPubMedGoogle Scholar
• 17 Sato K, Hatano T, Yamashiro K et al.. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations. Juntendo Parkinson Study Group.  Mov Disord. 2006;  21 1384-1395
  CrossrefPubMedGoogle Scholar
• 18 Koller W C, Hutton J T, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group.  Neurology. 1999;  53 1012-1019
  CrossrefPubMedGoogle Scholar
• 19 Calne D B, Teychenne P F, Claveria L E et al.. Bromocriptine in parkinsonism.  BMJ. 1974;  4 442-444
  PubMedGoogle Scholar
• 20 Holloway R G, Shoulson I, Fahn S et al.. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.  Arch Neurol. 2004;  61 1044-1053
  CrossrefPubMedGoogle Scholar
• 21 Brunt E R, Brooks D J, Korczyn A D, Montastruc J L, Stocchi F. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. 043 Study Group.  J Neural Transm. 2002;  109 489-502
  CrossrefPubMedGoogle Scholar
• 22 Goetz C G, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.  Mov Disord. 2005;  20 523-539
  CrossrefPubMedGoogle Scholar
• 23 Kurlan R. “Levodopa phobia:” a new iatrogenic cause of disability in Parkinson disease.  Neurology. 2005;  64 923-924
  CrossrefPubMedGoogle Scholar
• 24 Van Gerpen J A, Kumar N, Bower J H, Weigand S, Ahlskog J E. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.  Arch Neurol. 2006;  63 205-209
  CrossrefPubMedGoogle Scholar
• 25 The Parkinson Study Group . A controlled trial of rotigotine monotherapy in early Parkinson's disease.  Arch Neurol. 2003;  60 1721-1728
  CrossrefPubMedGoogle Scholar
• 26 Stocchi F, Hersh B P, Earl N L, Scott B L. Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson's disease. Poster presentation P894, Movement Disorder Society 10th International Congress of Parkinson's Disease and Movement Disorders Kyoto, Japan; 2006
  Google Scholar
• 27 Yoshioka M, Tanaka K, Miyazaki I et al.. The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals.  Neurosci Res. 2002;  43 259-267
  CrossrefPubMedGoogle Scholar
• 28 Le W D, Jankovic J, Xie W, Appel S H. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.  J Neural Transm. 2000;  107 1165-1173
  CrossrefPubMedGoogle Scholar
• 29 Frucht S, Rogers J D, Greene P E, Gordon M F, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole.  Neurology. 1999;  52 1908-1910
  PubMedGoogle Scholar
• 30 Arnulf I, Konofal E, Merino-Andreu M et al.. Parkinson's disease and sleepiness: an integral part of PD.  Neurology. 2002;  58 1019-1024
  PubMedGoogle Scholar
• 31 Gjerstad M D, Alves G, Wentzel-Larsen T, Aarsland D, Larsen J P. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease?.  Neurology. 2006;  67 853-858
  CrossrefPubMedGoogle Scholar
• 32 Giovannoni G, O'Sullivan J D, Turner K, Manson A J, Lees A J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies.  J Neurol Neurosurg Psychiatry. 2000;  68 423-428
  CrossrefPubMedGoogle Scholar
• 33 Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease.  Neurology. 2003;  61 422-423
  CrossrefPubMedGoogle Scholar
• 34 Pontone G, Williams J R, Bassett S S, Marsh L. Clinical features associated with impulse control disorders in Parkinson disease.  Neurology. 2006;  67 1258-1261
  CrossrefPubMedGoogle Scholar
• 35 Voon V, Hassan K, Zurowski M et al.. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease.  Neurology. 2006;  67 1254-1257
  CrossrefPubMedGoogle Scholar
• 36 Hunter K R, Boakes A J, Laurence D R, Stern G M. Monoamine oxidase inhibitors and L-dopa.  Br Med J. 1970;  3 388
  PubMedGoogle Scholar
• 37 Youdim M B, Edmondson D, Tipton K F. The therapeutic potential of monoamine oxidase inhibitors.  Nat Rev Neurosci. 2006;  7 295-309
  CrossrefPubMedGoogle Scholar
• 38 Waters C H, Sethi K D, Hauser R A, Molho E, Bertoni J M. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Zydis Selegiline Study Group.  Mov Disord. 2004;  19 426-432
  CrossrefPubMedGoogle Scholar
• 39 Parkinson Study Group . A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.  Arch Neurol. 2002;  59 1937-1943
  CrossrefPubMedGoogle Scholar
• 40 Parkinson Study Group . A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.  Arch Neurol. 2005;  62 241-248
  CrossrefPubMedGoogle Scholar
• 41 Wu R M, Murphy D L, Chiueh C C. Neuronal protective and rescue effects of deprenyl against MPP + dopaminergic toxicity.  J Neural Transm Gen Sect. 1995;  100 53-61
  PubMedGoogle Scholar
• 42 Youdim M B, Wadia A, Tatton W, Weinstock M. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.  Ann NY Acad Sci. 2001;  939 450-458
  PubMedGoogle Scholar
• 43 Nutt J G. Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.  Neurology. 2000;  55(suppl 4) S33-S37
  PubMedGoogle Scholar
• 44 Adler C H, Singer C, O'Brien C et al.. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.  Arch Neurol. 1998;  55 1089-1095
  CrossrefPubMedGoogle Scholar
• 45 Parkinson Study Group . Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients.  Ann Neurol. 1997;  42 747-755
  CrossrefPubMedGoogle Scholar
• 46 Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard P R. Tolcapone and fulminant hepatitis.  Lancet. 1998;  352 958
  PubMedGoogle Scholar
• 47 Schwab R S, England Jr A C, Poskanzer D C, Young R R. Amantadine in the treatment of Parkinson's disease.  JAMA. 1969;  208 1168-1170
  PubMedGoogle Scholar
• 48 Dallos V, Heathfield K, Stone P, Allen F A. Use of amantadine in Parkinson's disease: results of a double-blind trial.  BMJ. 1970;  4 24-26
  PubMedGoogle Scholar
• 49 Scotti G, Spinnler H. Amantadine and Huntington's chorea.  N Engl J Med. 1971;  285 1325-1326
  PubMedGoogle Scholar
• 50 Adler C H, Stern M B, Vernon G, Hurtig H I. Amantadine in advanced Parkinson's disease: good use of an old drug.  J Neurol. 1997;  244 336-337
  PubMedGoogle Scholar
• 51 Factor S A, Molho E S, Brown D L. Acute delirium after withdrawal of amantadine in Parkinson's disease.  Neurology. 1998;  50 1456-1458
  PubMedGoogle Scholar
• 52 Costa A, Peppe A, Dell'Agnello G et al.. Dopaminergic modulation of visual-spatial working memory in Parkinson's disease.  Dement Geriatr Cogn Disord. 2003;  15 55-66
  CrossrefPubMedGoogle Scholar
• 53 Molloy S A, Rowan E N, O'Brien J T et al.. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies.  J Neurol Neurosurg Psychiatry. 2006;  77 1323-1328
  CrossrefPubMedGoogle Scholar
• 54 Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.  Neurosci Biobehav Rev. 2006;  30 1-23
  CrossrefPubMedGoogle Scholar
• 55 Ravina B, Putt M, Siderowf A et al.. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.  J Neurol Neurosurg Psychiatry. 2005;  76 934-939
  CrossrefPubMedGoogle Scholar
• 56 Emre M, Aarsland D, Albanese A et al.. Rivastigmine for dementia associated with Parkinson's disease.  N Engl J Med. 2004;  351 2509-2518
  CrossrefPubMedGoogle Scholar
• 57 Hyson H C, Johnson A M, Jog M S. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study.  Mov Disord. 2002;  17 1318-1320
  CrossrefPubMedGoogle Scholar
• 58 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo M G. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.  Mov Disord. 2006;  21 704-707
  CrossrefPubMedGoogle Scholar
• 59 Senard J M, Brefel-Courbon C, Rascol O, Montastruc J L. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.  Drugs Aging. 2001;  18 495-505
  PubMedGoogle Scholar
• 60 Singer W, Sandroni P, Opfer-Gehrking T L et al.. Pyridostigmine treatment trial in neurogenic orthostatic hypotension.  Arch Neurol. 2006;  63 513-518
  CrossrefPubMedGoogle Scholar
• 61 Singer W, Opfer-Gehrking T L, Nickander K K, Hines S M, Low P A. Acetylcholinesterase inhibition in patients with orthostatic intolerance.  J Clin Neurophysiol. 2006;  23 476-481
  PubMedGoogle Scholar
• 62 Winge K, Fowler C J. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management.  Mov Disord. 2006;  21 737-745
  CrossrefPubMedGoogle Scholar
• 63 Zesiewicz T A, Helal M, Hauser R A. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease.  Mov Disord. 2000;  15 305-308
  CrossrefPubMedGoogle Scholar

Neal HermanowiczM.D. 

Department of Neurology, 105 Irvine Hall, University of California-Irvine

Irvine, CA 92697-4275